Visus Therapeutics Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
36
- Latest Deal Type
-
M&A
Visus Therapeutics General Information
Description
Developer of ophthalmic therapies intended to improve vision for people around the world. The company offers presbyopia-correcting eye drops with the potential to last hours and ophthalmic product candidates include applications in ocular surface disease, glaucoma, and age-related macular degeneration, enabling patients to correct the loss of near vision associated with presbyopia.
Contact Information
Website
www.visustx.comCorporate Office
- 2 Nickerson Street
- Suite 101
- Seattle, WA 98109
- United States
Corporate Office
- 2 Nickerson Street
- Suite 101
- Seattle, WA 98109
- United States
Visus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 12-Dec-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B2) | 01-Jun-2023 | Completed | Clinical Trials - Phase 3 | |||
| 3. Secondary Transaction - Private | Completed | Clinical Trials - Phase 3 | ||||
| 2. Early Stage VC (Series A2) | 10-Aug-2021 | $20M | $56M | Completed | Clinical Trials - Phase 3 | |
| 1. Early Stage VC (Series A) | 09-Mar-2021 | $36M | $36M | Completed | Clinical Trials - Phase 3 |
Visus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 |
Visus Therapeutics Comparisons
Industry
Financing
Details
Visus Therapeutics Competitors (4)
One of Visus Therapeutics’s 4 competitors is ONL Therapeutics, a Venture Capital-Backed company based in Ann Arbor, MI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Opus Genetics | Formerly VC-backed | Durham, NC | ||||
| Orasis Pharmaceuticals | Venture Capital-Backed | Ponte Vedra Beach, FL | ||||
| TearClear | Venture Capital-Backed | Princeton, NJ |
Visus Therapeutics Patents
Visus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025010288-A2 | Hyaluronic acid based drug delivery systems | Inactive | 03-Jul-2023 | ||
| WO-2025010288-A3 | Hyaluronic acid based drug delivery systems | Inactive | 03-Jul-2023 | ||
| AU-2024303954-A1 | Synthesis of 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminium salts | Pending | 16-Jun-2023 | ||
| EP-4727533-A2 | Synthesis of 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminium salts | Pending | 16-Jun-2023 | ||
| WO-2024259258-A2 | Synthesis of 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminium salts | Inactive | 16-Jun-2023 | C07D233/56 |
Visus Therapeutics Signals
Visus Therapeutics Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EQT Life Sciences | Venture Capital | Minority | ||
| Gershon Capital | Venture Capital | Minority | ||
| Johnson & Johnson JJDC | Corporate Venture Capital | Minority | ||
| Planet Innovation | PE-Backed Company | Minority | ||
| Qima Ventures | Impact Investing | Minority |
Visus Therapeutics Acquisitions (1)
Visus Therapeutics’s most recent deal was a Merger/Acquisition with ViewPoint Therapeutics. The deal was made on 28-Jul-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ViewPoint Therapeutics | 28-Jul-2022 | Merger/Acquisition | Drug Discovery |
Visus Therapeutics FAQs
-
When was Visus Therapeutics founded?
Visus Therapeutics was founded in 2019.
-
Where is Visus Therapeutics headquartered?
Visus Therapeutics is headquartered in Seattle, WA.
-
What is the size of Visus Therapeutics?
Visus Therapeutics has 36 total employees.
-
What industry is Visus Therapeutics in?
Visus Therapeutics’s primary industry is Drug Discovery.
-
Is Visus Therapeutics a private or public company?
Visus Therapeutics is a Private company.
-
What is Visus Therapeutics’s current revenue?
The current revenue for Visus Therapeutics is .
-
How much funding has Visus Therapeutics raised over time?
Visus Therapeutics has raised $56M.
-
Who are Visus Therapeutics’s investors?
EQT Life Sciences, Gershon Capital, Johnson & Johnson JJDC, Planet Innovation, and Qima Ventures are 5 of 9 investors who have invested in Visus Therapeutics.
-
Who are Visus Therapeutics’s competitors?
ONL Therapeutics, Opus Genetics, Orasis Pharmaceuticals, and TearClear are competitors of Visus Therapeutics.
-
When was Visus Therapeutics acquired?
Visus Therapeutics was acquired on 12-Dec-2024.
-
Who acquired Visus Therapeutics?
Visus Therapeutics was acquired by Tenpoint Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process